Search Results
Your search for ASCO,ASCO matches 21248 pages
Showing 14751 - 14800Anti–PD-L1 Antibody Durvalumab in Advanced Urothelial Bladder Cancer
In a phase I/II study reported in the Journal of Clinical Oncology, Massard et al found that the anti–PD-L1 (programmed cell death ligand 1) antibody durvalumab was active in patients with previously treated advanced urothelial bladder cancer. Objective response appeared to be confined to patients...
Quality of Life With Nivolumab vs Everolimus in Advanced Renal Cell Carcinoma
Patients with previously treated advanced renal cell carcinoma receiving nivolumab (Opdivo) in the phase III CheckMate 025 trial had improved health-related quality of life compared with those receiving everolimus (Afinitor), as reported by David Cella, PhD, of Northwestern University, Chicago, et...
Final Results of METEOR Trial: Cabozantinib vs Everolimus in Advanced Renal Cell Carcinoma
As reported by Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, et al in The Lancet Oncology, the final results of the phase III METEOR trial indicate significantly improved overall survival with cabozantinib (Cabometyx) vs everolimus (Afinitor) in patients with advanced renal cell carcinoma...
Pancreatic Cancer Action Network Appoints Four Leaders to Its Scientific and Medical Advisory Board
The Pancreatic Cancer Action Network has added four leaders from across the country to its Scientific and Medical Advisory Board. “Members of the Pancreatic Cancer Action Network Scientific and Medical Advisory Board have committed their careers to change the course of a deadly and complex...
ASTRO Members Elect Five New Officers to Board of Directors
Members of the American Society for Radiation Oncology (ASTRO) have elected five new officers to the Society’s Board of Directors, including President-Elect, Secretary/Treasurer-Elect, and Vice-Chairs of three of ASTRO’s five councils (Clinical Affairs and Quality, Education, and Government...
Multiple Strategies for Colorectal Cancer Screening Offer an Opportunity for Shared Decision-Making
Screening for colorectal cancer should start at age 50 and continue until age 75, according to the updated recommendation from the U.S. Preventive Services Task Force (USPSTF).1 “Exactly what screening gets done is something that doctors and patients should decide together,” USPSTF Chair Kirsten...
Multiple Means to Realize the Benefits of Colorectal Cancer Screening
In an updated recommendation statement, the U.S. Preventive Services Task Force (USPSTF) continues to strongly recommend screening for colorectal cancer for asymptomatic adults aged 50 through 75; but rather than emphasize specific screening strategies, it notes there are multiple screening...
Study Shows Women Who Received Cancer Screening Invitation Letters Are More Likely to Have a Pap Test
Receiving an invitation to get screened for cervical cancer is associated with a greater likelihood of getting screened, according to a study published by Tavasoli et al in Preventive Medicine. The study explored the impact of invitation and reminder letters on cervical cancer screening...
FDA Approves Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Platinum-Containing Chemotherapy
The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda), an anti–PD-1 (programmed cell death protein 1) therapy, at a fixed dose of 200 mg every 3 weeks, for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma with...
Julienne Bower, PhD, Named Professor of Psychobiology in Cousins Center for Psychoneuroimmunology at UCLA
The Cousins Center for Psychoneuroimmunology at the University of California, Los Angeles (UCLA) Semel Institute for Neuroscience and the UCLA Jonsson Comprehensive Cancer Center (JCCC) announced that Julienne Bower, PhD, Co-Director of the JCCC Patients and Survivors Program, Professor of...
The Building Block of Life, Brick by Brick
BookmarkTitle: The Gene: An Intimate HistoryAuthor: Siddhartha Mukherjee, MDPublisher: ScribnerPublication date: May 2016Price: $32.00; hardcover, 608 pagesOn February 28, 1953, James Watson and Francis Crick entered The Eagle, a favorite watering hole for researchers working at the University of...
David LeDuc Named Executive Director of Addario Lung Cancer Foundation
The Bonnie J. Addario Lung Cancer Foundation (ALCF) has announced that it has appointed David LeDuc as its new Executive Director. Mr. LeDuc most recently served as the Senior Director of Strategic Alliances for the Addario Lung Cancer Medical Institute (ALCMI), a partner foundation to ALCF, where ...
Reference Laboratory Identifies Change in Pattern of Breast Cancer HER2 Fluorescence in Situ Hybridization Results
The most recent (2013) ASCO/College of American Pathologists (AC) guidelines for HER2 testing resulted in different rates of HER2 positivity compared with the use of the U.S. Food and Drug Administration (FDA) or 2007 AC guidelines, according to a study reported in the Journal of Clinical Oncology...
Integrating Early Palliative Medicine Into Oncology Care to Improve Patients’ Quality of Life
At the 2015 Palliative Care in Oncology Symposium in Boston, Vicki Jackson, MD, MPH, Chief in the Division of Palliative Care and Geriatrics at Massachusetts General Hospital, Co-Director of the Harvard Center for Palliative Care, and Associate Professor of Medicine at Harvard Medical School,...
ASH Commits $3 Million Annually to Help Preserve Critical Blood Disease Research
With a $3 million annual commitment to support promising blood disease research amid limited National Institutes of Health (NIH) funding, the American Society of Hematology (ASH) has announced the formal establishment of the ASH Bridge Grant program after an extended 4-year pilot study. ASH also...
FDA Approves Sofosbuvir/Velpatasvir for Treatment of Chronic Hepatitis C Virus Infection
The U.S. Food and Drug Administration (FDA) approved Epclusa (sofosbuvir at 400 mg/velpatasvir at 100 mg) on June 28, 2016, to treat adult patients with chronic hepatitis C virus both with and without cirrhosis. For patients with moderate to severe cirrhosis (decompensated cirrhosis),...
FDA Approves First HPV Test for Use With SurePath Preservative Fluid
On July 7, 2016, the U.S. Food and Drug Administration (FDA) approved the Roche cobas HPV Test as the first test for human papillomavirus (HPV) that can be used with cervical cells obtained for a Papanicolau (Pap) test and collected in SurePath Preservative Fluid. The FDA approves HPV tests to be...
Juno Therapeutics to Resume JCAR015 Phase II ROCKET Trial After FDA Clinical Hold
Juno Therapeutics, Inc., announced on July 12, 2016, that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on the phase II clinical trial of JCAR015 (known as the ROCKET trial; clinicaltrials.gov identifier NCT02535364) in adult patients with relapsed or refractory B-cell...
NCCN Imaging Appropriate Use Criteria to Be Integrated Into National Decision Support Company’s CareSelect Imaging
The National Comprehensive Cancer Network® (NCCN) is collaborating with National Decision Support Company (NDSC) to integrate the NCCN Imaging Appropriate Use Criteria (AUC) into NDSC’s CareSelect Imaging to allow for access to imaging recommendations, adapted from the NCCN Clinical Practice...
Maryland Proton Treatment Center Appoints Charles B. Simone II, MD, New Medical Director
Charles B. Simone II, MD, has been named the new Medical Director of the Maryland Proton Treatment Center (MPTC). Dr. Simone will begin work in November 2016. As Medical Director, Dr. Simone will continue to define and implement processes ensuring that MPTC is integrated into the radiation...
NCI Awards $12 Million for Multi-Institution Breast Cancer Genetics Study
A large study headed by researchers from the Keck School of Medicine of the University of Southern California (USC), Vanderbilt University, and Boston University received $12 million in funding to examine why African American women die at a higher rate from breast cancer and have more aggressive...
Epithelial Cells on the Tail Fin of Genetically Engineered Zebrafish
Image depicts hundreds of live cells from a tiny bit of skin on the tail fin of a genetically engineered adult zebrafish. The cells have been labeled with a new fluorescent imaging tool called Skinbow. It uniquely color codes cells by getting them to express genes encoding red, green, and blue...
New Analysis Shows Advertising by U.S. Cancer Centers Has Soared Over Past Decade
American cancer centers promoting their services dramatically increased their advertising spending from 2005 to 2014, with the bulk of the spending by for-profit organizations, according to the results of a study published by Vater et al in JAMA Internal Medicine.1 Small Percentage Responsible for...
Actively Recruiting Clinical Trials Focused on the Role of Obesity in Cancer
Study Title: A Pilot Study of a Protein-Sparing Modified Fast for Weight Loss in Obese Endometrial Cancer Survivors Study Type: Pilot/interventional/single-group assignment Study Sponsor and Collaborators: Case Comprehensive Cancer Center, National Cancer Institute Purpose: To study whether the...
2016 - 2017 Oncology Meetings
AUGUST The 33rd World Congress of Internal Medicine (WCIM)August 22-25 • Bali, IndonesiaFor more information: www.wcimbali2016.org 16th World Congress on Cancers of the SkinAugust 31-September 3 • Vienna, Austria For more information: www.wccs2016.com 12th National Lymphedema Network International...
13 Mid-Career Clinical Investigators Receive 2016 NCI Cancer Clinical Investigator Team Leadership Award
At the National Cancer Institute (NCI) Clinical Trials and Translational Research Advisory Committee (CTAC) meeting held on July 13, 2016, 13 recipients were presented with the 2016 NCI Cancer Clinical Investigator Team Leadership Award (CCITLA). The award recognizes and supports outstanding...
OmniSeq Receives New York CLEP Approval for 144-Gene Comprehensive Panel, Partners With Cure Forward
OmniSeq, a subsidiary of Roswell Park Cancer Institute, received New York State Clinical Laboratory Evaluation Program (CLEP) approval for its OmniSeq Comprehensive panel, a 144-gene, pan-cancer, next-generation sequencing tumor-profiling diagnostic panel to guide oncology treatment...
Andrew Olshan, PhD, Elected President of the Society for Epidemiologic Research
Andrew Olshan, PhD, Associate Director of Population Sciences and Co-Leader of the Epidemiology Program at UNC Lineberger Comprehensive Cancer Center, has been elected President of the Society for Epidemiologic Research, the oldest and largest general epidemiology society in North America. He will ...
Making a Difference in the Lives of Others
Quyen D. Chu, MD, MBA, FACS, this year’s recipient of ASCO’s Humanitarian Award, lives by the axiom that “One person can make a positive difference in the lives of others.” Although the term has become cliché, the experiences in Dr. Chu’s life and oncology career prove just how profound and...
Abhishek Aphale, MD, Joins Department of Dermatology at Fox Chase Cancer Center
Abhishek Aphale, MD, has been appointed Assistant Professor of Dermatology at Fox Chase Cancer Center. Dr. Aphale earned his medical degree from the Robert Wood Johnson Medical School of Rutgers University. He completed his residency training at the University of Michigan and a Procedural...
Rajeswari Nagarathinam, MD, Joins Department of Pathology at Fox Chase Cancer Center
Rajeswari Nagarathinam, MD, has joined the Department of Pathology at Fox Chase Cancer Center, focusing on both surgical pathology and cytopathology. Dr. Nagarathinam is currently completing a surgical oncologic pathology fellowship at Fox Chase. Dr. Nagarathinam is a licensed, board-certified...
Safety Concerns Weigh Heavily in Elderly Patients With Cancer
Active pharmacovigilance in detecting and assessing the safety signals related to drugs and devices, and disseminating those findings to relevant stakeholders, is an important component in delivering safe, high-quality care in the cancer setting. To reach a better understanding of this issue,...
Ribociclib Receives FDA Breakthrough Therapy Designation for Treatment of Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ribociclib in combination with letrozole for the treatment of hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. Ribociclib...
Androgen-Deprivation Therapy May Increase Mortality in African American Men With Favorable-Risk Prostate Cancer
In a retrospective study analyzing patients' medical records, researchers at Brigham and Women's Hospital (BWH) found that race significantly affected longevity by increasing the likelihood of death after receiving androgen-deprivation therapy. These findings were published by Kovtun et al in...
Metabolic Gene-Expression Profile May Identify Kidney Cancer Patients Unlikely to Benefit From Nivolumab
Renal cell carcinomas (RCC) positive for the protein programmed death ligand 1 (PD-L1) from patients who did not respond to treatment with the anti–PD-1 therapeutic nivolumab (Opdivo) had significantly higher expression of genes associated with metabolism, compared with PD-L1–positive...
Is Post-Transplantation Cyclophosphamide Disruptive Technology?
There was a time when transplantation across human leukocyte antigen (HLA) barriers was fraught with so much difficulty that many thought it was impossible and we should stop trying. However, most patients do not have an HLA-matched sibling donor, and death was therefore certain if they had a...
Effects of the Global Economic Crisis on Cancer Care
The global economic crisis beginning in 2008 was associated with substantial public health effects, especially with respect to mental health.1–3 Nevertheless, there is also evidence of a paradoxical association between recessions and reduced all-cause mortality, in part because of reductions in...
10 New ASTRO Fellows Named in 10th Anniversary of FASTRO Designation
Ten distinguished members of the American Society for Radiation Oncology (ASTRO) have been named ASTRO Fellows, in the 10th anniversary year that the designation has been awarded. The 2016 class of Fellows will be recognized at an awards ceremony during ASTRO’s 58th Annual Meeting, to be held...
Spotlight on Women Who Conquer Cancer
Women Who Conquer Cancer is a group dedicated to advancing cancer research by supporting young women researchers early in their careers through Conquer Cancer Foundation of ASCO Young Investigator Awards (YIAs). These 1-year grants give promising researchers the boost they need to get started on...
Making a Difference in Cancer Care With You: Daniel Hayes’ Presidential Theme
“Are you a member of ASCO?” I distinctly remember being asked that question in 1984, during my second year as a fellow at what was then the Sidney Farber (now Dana-Farber) Cancer Institute. My first reaction: “What’s an ASCO?” Turned out it was a) the Society that many of my mentors had or would...
Survivorship Resources for Providers and Patients
ASCO offers a product that combines provider and patient information about cancer survivorship. Providing High Quality Survivorship Care in Practice: An ASCO Guide aims to assist oncologists and other clinicians with implementing high-quality survivorship care programs within their practice. The...
Daniel F. Hayes, MD, FASCO, Leader in Translational Research, Begins Term as ASCO President
In 1995, Daniel F. Hayes, MD, FASCO, gathered with several other oncologists at a conference center in San Francisco to begin writing the first-ever ASCO guidelines on cancer treatment. He and his colleagues felt like pioneers scouting uncharted frontier. “I’ll never forget, that first hour or so, ...
ASCO and CancerLinQ Participated in Landmark Cancer Moonshot Summit
ASCO Chief Executive Officer Clifford A. Hudis, MD, FASCO, and CancerLinQ LLC Chief Executive Officer Kevin Fitzpatrick attended Vice President Joe Biden’s Cancer Moonshot Summit at Howard University on Wednesday, June 29, 2016. Along with leaders and stakeholders across the cancer research and...
Anti–Interleukin-1 Alpha Antibody MABp1 Improves Outcomes Significantly Over Placebo in Advanced Colorectal Cancer
A novel anti–interleukin-1 alpha (IL-1α) antibody has shown a significant impact on symptoms and a high level of safety and tolerability in patients with advanced colorectal cancer, according to phase III data presented by Hickish et al at the European Society for Medical Oncology’s 18th World...
Chemoradiotherapy After Surgery for Gastric Cancer Shows Similar Outcomes to Postoperative Chemotherapy
Postoperative treatment intensification with chemoradiotherapy does not achieve better outcomes when compared with postoperative chemotherapy in patients with gastric cancer who have already undergone preoperative chemotherapy, according to phase III data presented by Marcel Verheij, MD, PhD, et...
Phase III RESORCE Study Data Show Regorafenib Improves Overall Survival in Previously Treated Patients With Unresectable Liver Cancer
Results from the phase III RESORCE trial show that regorafenib (Stivarga) tablets achieved a median overall survival improvement in patients with unresectable hepatocellular carcinoma that progressed after treatment with sorafenib (Nexavar) tablets. The study, presented by Jordi Bruix, MD, et al...
Anti–PD-L1 Immunotherapy Shows Response in Microsatellite-Stable Metastatic Colorectal Cancer in Combination With MEK Inhibition
Anti–PD-L1 (programmed death ligand 1) immunotherapy may achieve a response in patients with microsatellite-stable metastatic colorectal cancer if combined with a MEK inhibitor, according to phase I data presented at the European Society for Medical Oncology (ESMO) 18th World Congress on...
New Study Finds Increase in Imaging After Thyroid Cancer Treatment Identifies Recurrence but May Not Improve Survival
More imaging after thyroid cancer treatment identifies recurrence, but it does not always improve survival, a new study published by Banerjee et al in The BMJ suggests. Researchers from the University of Michigan Comprehensive Cancer Center looked at 28,220 patients diagnosed with...
African American Women More Likely to Choose Autologous Breast Reconstruction Over Implant-Based Reconstruction
African American women undergoing mastectomy for breast cancer are more likely than white women to undergo autologous breast reconstruction using their own tissue, rather than implant-based reconstruction, reported Sharma et al in Plastic and Reconstructive Surgery. “African American race...
AAPM 2016: Somatic Mutations and PET-Based Radiomic Features in Non–Small Cell Lung Cancer
A cutting-edge method of extracting big data from positron-emission tomography (PET) images can provide additional information to quantify lung tumors caused by a genetic mutation. This information could help guide the most effective treatment, suggest findings of a study of nearly 350 patients...
